Cover Image
市場調查報告書

Amicus Therapeutics, Inc.:開發中產品分析

Amicus Therapeutics, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224669
出版日期 內容資訊 英文 54 Pages
訂單完成後即時交付
價格
Back to Top
Amicus Therapeutics, Inc.:開發中產品分析 Amicus Therapeutics, Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月31日 內容資訊: 英文 54 Pages
簡介

Amicus Therapeutics, Inc.,研究、開發、銷售人類遺傳病的藥理性伴護蛋白的小分子藥、口服藥。該公司還有開發改善溶小體儲積症和神經退行性疾病等治療方法的新藥。該公司主要產品migalastat HCl──用於法布瑞氏症的治療──現在,處於臨床實驗的第三階段。

本報告提供美國的生物醫藥品企業、Amicus Therapeutics, Inc.(Amicus Therapeutics)的醫藥品的研究開發的進展相關分析、該公司的產品平台結構,及臨床實驗的整體進展、主要開發中產品簡介與開發情形、該公司簡介調查與最新趨勢等。

目錄

Amicus Therapeutics, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台、檢討

  • 各開發階段的開發中產品
  • 開發中產品:單劑治療藥
  • 開發中產品:並用治療模式
  • 開發中產品:合作夥伴產品
    • 合作夥伴產品/並用治療模式

開發中產品的概要

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

藥物簡介

  • migalastat hydrochloride
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • migalastat hydrochloride + agalsidase alfa
  • duvoglustat hydrochloride+agurikoshidazeα
  • duvoglustat hydrochloride+ATB-200
  • afegostat tartrate
  • afegostat tartrate + ERT
  • AT-3375
  • ATB-200
  • Chaperone-ERT化合物
  • laronidase+Chaperone
  • migalastat hydrochloride+酵素替代療法
  • 溶小體儲積症基因改造型酵素
  • 神經退化性疾病小分子

開發平台分析

  • 各標靶
  • 各投藥法
  • 各分子類型
  • 各作用機制

開發中產品的最新趨勢

開發暫停的產品

企業的聲明

公司所在地及子公司

  • 總公司
  • 其他的公司所在地、子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07265CDB

Summary

Global Markets Direct's, 'Amicus Therapeutics, Inc. - Product Pipeline Review - 2015', provides an overview of the Amicus Therapeutics, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Amicus Therapeutics, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Amicus Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Amicus Therapeutics, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Amicus Therapeutics, Inc.'s pipeline products

Reasons to buy

  • Evaluate Amicus Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Amicus Therapeutics, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Amicus Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Amicus Therapeutics, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Amicus Therapeutics, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Amicus Therapeutics, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Amicus Therapeutics, Inc. Snapshot
    • Amicus Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • Amicus Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Amicus Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Amicus Therapeutics, Inc. - Pipeline Products Glance
    • Amicus Therapeutics, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Amicus Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • Amicus Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Amicus Therapeutics, Inc. - Drug Profiles
    • migalastat hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (migalastat hydrochloride + agalsidase alfa)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • duvoglustat hydrochloride + alglucosidase alfa
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (duvoglustat hydrochloride + ATB-200)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • afegostat tartrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • afegostat tartrate + ERT
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AT-3375
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATB-200
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Chaperone-ERT Combinations
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • laronidase + chaperone
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • migalastat hydrochloride + Enzyme Replacement Therapy Biobetter
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme for Lysosomal Storage Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Neurodegenerative Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Amicus Therapeutics, Inc. - Pipeline Analysis
    • Amicus Therapeutics, Inc. - Pipeline Products by Target
    • Amicus Therapeutics, Inc. - Pipeline Products by Route of Administration
    • Amicus Therapeutics, Inc. - Pipeline Products by Molecule Type
    • Amicus Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • Amicus Therapeutics, Inc. - Recent Pipeline Updates
  • Amicus Therapeutics, Inc. - Dormant Projects
  • Amicus Therapeutics, Inc. - Company Statement
  • Amicus Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Amicus Therapeutics, Inc., Key Information
  • Amicus Therapeutics, Inc., Key Facts
  • Amicus Therapeutics, Inc. - Pipeline by Indication, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Amicus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Amicus Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Amicus Therapeutics, Inc. - Partnered Products in Pipeline, 2015
  • Amicus Therapeutics, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Amicus Therapeutics, Inc. - Pre-Registration, 2015
  • Amicus Therapeutics, Inc. - Phase III, 2015
  • Amicus Therapeutics, Inc. - Phase II, 2015
  • Amicus Therapeutics, Inc. - Preclinical, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Target, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Route of Administration, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Molecule Type, 2015
  • Amicus Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Amicus Therapeutics, Inc. - Recent Pipeline Updates, 2015
  • Amicus Therapeutics, Inc. - Dormant Developmental Projects,2015
  • Amicus Therapeutics, Inc., Subsidiaries

List of Figures

  • Amicus Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Stage of Development, 2015
  • Amicus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015
  • Amicus Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Top 10 Target, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Amicus Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Amicus Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top